

## Review Article

# Intermittent fasting - a potential approach to modulate the gut microbiota in humans? A systematic review

Kate Llewellyn-Waters<sup>a,\*</sup> and Mohammad M. Abdullah<sup>b</sup>

<sup>a</sup>Lansdown Clinic, Bath, United Kingdom

<sup>b</sup>Department of Food Science and Nutrition, Kuwait University, Kuwait

**Abstract.** Research on gut microbiota has increased in popularity over the past decade, with evidence associating different dietary habits with changes in the makeup of the rich ecosystem of microorganisms that performs a variety of functions and induces a range of health effects, within and well beyond the gastrointestinal tract. Similarly, intermittent fasting (IF), an umbrella term describing various regimens of periods of voluntary abstinence from food and drink, has classically been associated with favourable impacts on cardiovascular risk factors, body weight, circadian biology, and, more recently, the gut health. The objective of this PRISMA systematic review was to summarize the peer-reviewed literature of clinical trials related to the impact of IF regimens on the gut microbiota. A MEDLINE search was conducted using PubMed and the keywords “intermittent fasting”, “gut microbiota”, “microbes”, and others. Whilst the field is still in its infancy, an emerging body of evidence suggests beneficial effects of IF on the health of the gut through increasing the microbial diversity and abundance, with possible clinical implications related to improving the immune function and ameliorating the metabolic status. Further research in larger clinical trials is warranted before practical recommendations for the public health can be made.

Keywords: Intermittent fasting, periodic fasting, alternate-day fasting, whole-day fasting, time-restricted feeding, gut microbiota, microbes

## 1. Background

Both human and animal studies demonstrate a beneficial impact of intermittent fasting (IF), a term describing several regimens of periods of voluntary abstinence from food and drink, on various aspects of health. IF regimens can be categorized into fasting for up to 24 hours once or twice a week with ad libitum food intake for the remaining days, known as

periodic prolonged fasting (PF) or intermittent calorie restriction (ICR) [1]; eating for 8 hours then fasting for the other 16 hours of the day (time-restricted feeding, TRF); and alternating between feasting and fast days (alternate-day fasting, ADF) [2, 3] (Table 1). IF has classically been recognized to ameliorate obesity [2], insulin resistance [4], dyslipidemia [5], blood pressure [4] and inflammation [6]. More recently, IF has been shown to also benefit the gut microbiota [7], a term describing the trillions of microorganisms (bacteria, viruses, protozoa, and fungi), which are present in the human gut and are involved in

\*Corresponding author: Kate Llewellyn-Waters, MSc. Lansdown Clinic, Bath United Kingdom. Tel.: +44 7732 831742; E-mail: katelewellynwaters@icloud.com.

Table 1  
Comparison of different types of intermittent fasting

| Type of IF              | Description  | Metabolic states involved   |
|-------------------------|--|---|
| Alternate day fasting   | Alternating feast (ad lib intake) and fast days ( $\leq 25\%$ of energy needs)                       | Fed, post-absorptive, fasting (short duration, likely $< 36$ hours between meals)                           |
| Time-restricted fasting | Eating only during certain time periods (i.e., 8 hours), then fasting for remaining hours of the day | Fed, post-absorptive (maximum duration between meals is usually $< 16$ hours)                               |
| Periodic fasting        | Fasting for up to 24 hours once or twice a week with ad lib intake on the remaining days             | Fed, post-absorptive, fasting (up to 48 hours between meals depending on whether fast days are consecutive) |

virtually all aspects of health [8, 9]. This is a vast and complex microbial community, with over 1000 bacterial species identified and approximately 160 species found in the gut of any one person [10], and the most abundant bacterial phyla in the adult gastrointestinal tract are Firmicutes and Bacteroidetes [11, 12].

The gut microbiota provides many benefits to the host, such as the biosynthesis of certain vitamins and essential amino acids, and the generation of short-chain fatty acids (SCFAs) as metabolic by-products from undigested food components [13]. SCFAs, including butyrate, propionate, and acetate are a major source of energy for the intestinal cells and may strengthen the intestinal barrier [14] and improve the gut integrity [15], which is paramount in promoting optimum colonic health and function; resulting in better immunity [16]. SCFA production is influenced by gut microbiota composition and diet, with primarily butyrate and acetate decreasing the inflammatory response, whilst increasing the anti-inflammatory response of the adaptive immune system [17]. In addition, butyrate methylates promoter regions, thus influencing gene expression in enterocytes, macrophages and immune cells; deficient SCFA can disrupt these processes, which can lead to an autoimmune response and disease [17]. Furthermore, SCFA and butyrate specifically controls the function and size of the regulatory T cell network by stimulating the induction and fitness of regulatory T cells in the gut [18–20]. In addition, the microbiota is involved in many critical functions to ensure that optimum immune responses can be produced, including aiding development and maturation of lymphoid structures and potentiation of the function of innate immune cells [21]. Whilst, the microbiota is critical for maturation of the immune system, in return, the latter determines the composition of the microbiota. As such, disrupted microbial composition has been associated with several diseases in humans. However, the intricate immune/microbial interactions make it difficult to determine whether dysbiosis, the imbalance of gut microbiota, is a cause

and/or a consequence of immune dysregulation and disease initiation or progression [21].

Diet is reported as a major factor influencing gut microbiota and several studies have investigated the impact of different dietary components, including carbohydrates, predominantly fibre, and plant-based diets, on the gut microbiota [22–26]. Nuts and other plant-based foods that are abundant in polyunsaturated and monounsaturated fats and, occasionally, polyphenols and other phytochemicals have been shown to increase bacterial diversity, as well as the beneficial butyrate-producing bacteria revealing a positive metabolic effect [27–28].

With rapidly advancing screening used to analyse and differentiate complex ecosystems, the role of microbiota in a significant number of gastrointestinal diseases has become increasingly clear [29, 30]. Dysbiosis may contribute to the pathogenesis of a vast range of such diseases, including inflammatory bowel disease (IBD), celiac disease, colorectal cancer, *Clostridium difficile* infection, and obesity [31]. For instance, studies [32–35] have found IBD patients to have less bacterial diversity in the gut and reduced numbers of Bacteroidetes and Firmicutes, potentially leading to decreased concentrations of butyrate that is, along with other SCFAs, believed to have a direct anti-inflammatory effect [33, 36, 37]. Greater diversity in the microbial community has also been associated with a healthier gut microbiome [38–40]; a diverse array of bacteria promotes microbiome capability, and is imperative for a healthy host–microorganism balance to ensure optimal metabolic and immune function.

For this reason, the gut microbiome has become a promising target for prediction, prevention and treatment of diseases [8]. Given that it is evident that diet is a significant modulator of the gut health and microbiota diversity [22–26], and that dietary restrictions such as IF may also contribute to such effect [9], the objective of this review was to summarize the peer-reviewed literature of clinical trials related to the impact of IF regimens on the gut microbiota.




Fig. 1. PRISMA 2009 Flow Diagram.

## 2. Methods

The design of the study is a qualitative systematic review in line with the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) checklist (Fig. 1). A literature review was performed independently by two reviewers, K LW and MA using PubMed. Search criteria included clinical trials published in English between January 2000 and April 2020 with the keywords “intermittent fasting”, “periodic fasting”, “time-restricted”, “alternate-day fasting”, “whole day fasting”, “gut microbiota”, and

“microbes”. References were reviewed from seminal papers to identify additional articles.

## 3. Results and discussion

Based on the inclusion criteria, 98 clinical studies were identified and six articles were included in this review [8, 41–45] (Fig. 1). Other studies were excluded as they did not specifically examine the role of IF on the gut microbiota. The excluded articles investigated the effect of alternative nutrients’

125

126

127

128

129

130

131

132

133

134

135

136

137

138

139

140

141

142

143

144

Table 2  
Summary of studies included in the present review

| Reference                     | Participants (n)                         | Duration and type of fasting                                   | Comparison group               | Change in microbial Composition  |
|-------------------------------|--|--|--------------------------------|--|
| He et al. (2019) [8]          | Healthy adults aged 18–40 years (n = 16) | 1 week: water-only fasting (n = 6)                             | 1 week: juice fasting (n = 10) | ↓ <i>Fusobacterium</i><br>water-only fasting<br>↔ <i>Akkermansia</i><br>water-only fasting<br>↔ juice fasting  |
| Remely et al. (2015) [41]     | Overweight (n = 13)                      | CR and PF/TRF (non-traditional fasting regimen) (600–800 kcal) | None                           | ↑ <i>Lactobacillus</i><br>↑ <i>Enterobacteria</i><br>↑ <i>Akkermansia</i>  |
| Cignarella et al. (2018) [42] | Adults with MS (n = 16)                  | 15 days: ADF   | 15 days: ad libitum            | ↑ <i>Bacteroides</i><br>↑ <i>Lactobacillus</i><br>↑ <i>Prevotella</i> (fasting group)  |
| Özkul et al. (2019) [43]      | Healthy adults aged 31–56 years (n = 9)  | 29 days: Ramadan fasting /TRF                                  | None                           | ↑ <i>Bacteroides</i><br>↑ <i>Akkermansia</i>   |
| Gabel et al. (2020) [44]      | Obese adults (n = 14)                    | 12 weeks: TRF  | None                           | ↔  |
| Özkul et al. (2020) [45]      | Healthy adults (n = 9)                   | 29 days: Ramadan fasting /TRF                                  | None                           | ↑ <i>Bacteroides</i><br>↑ <i>Butyrivibrio</i><br>↑ <i>Faecalibacterium</i><br>↑ <i>Roseburia</i><br>↑ <i>Allobaculum</i><br>↑ <i>Eubacterium</i><br>↑ <i>Dialister</i><br>↑ <i>Erysipelotrichi</i> |

Abbreviations: ADF, alternate-day fasting; CR, calorie restriction; MS, multiple sclerosis; PF, periodic fasting; TRF, time-restricted feeding; ↑, statistically significant increase ( $p < 0.05$ ); ↔, no change.

or foods such as gluten, yogurt, high-fat and/or high-sugar diet on the gut microbiota. Main microbiota-related findings of studies included in the present review are summarized in Table 2 and are discussed below.

Cignarella et al. 2008 [42] initiated a 15-day randomized controlled pilot trial to multiple sclerosis (MS) subjects experiencing relapse; where seventeen subjects were equally randomized to ADF vs ad libitum diet. No bacteria were significantly different at day 15 between the two groups, but the abundance of *Faecalibacterium*, *Lachnospiraceae incertae sedis* and *Blautia* showed an increasing trend after 15 days of IF [42]. *Faecalibacterium* and *Blautia* belong to the *Clostridia clusters XIV* and *XIVa* (in the Firmicutes phylum) and have been shown to increase regulatory T cell (Treg) accumulation in the colon [46]. These bacteria are important as they produce acetate and have been observed to be decreased in MS subjects [47]. As such, the increase in the *Clostridia clusters XIV* and *XIVa* with IF may function to counterbalance the dysbiosis usually observed in MS [42].

In a 2019 study of sixteen healthy subjects aged 18–40 years and have BMI  $>18.5 \text{ kg/m}^2$ , six

individuals were allocated to a water-only fast and ten were assigned a juice fast for one week [8]. Daily stool sample collection, prior to and post fasting, started from two weeks before fasting until four weeks after. The authors hypothesized that water only fasting may be a potential therapeutic strategy in reducing *Fusobacterium*, which has been shown to promote colorectal cancer [8]. However, the differential abundance findings suggest that the impact of fasting on individual microbial taxa is unique and personalized. Despite this individualized effect, relative abundance of *Fusobacterium* was decreased across all participants in group 1 ( $P < 0.05$ ) when compared with pre-fasting controls. This finding was not reported in group 2 ( $P > 0.05$ ), however pre-fasting relative abundance of *Fusobacterium* was increased in group 1 compared with group 2 participants. In all participants, post water-only fasting *Fusobacterium* remained consistently reduced. In addition, eight out of ten subjects were not affected by juice fasting, with no increased homogeneity between subjects. These findings suggest that water-only fasting may have a long-lasting effect on the microbiota and a more homogenous microbial community; indicating

145  
146  
147  
148  
149  
150  
151  
152  
153  
154  
155  
156  
157  
158  
159  
160  
161  
162  
163  
164  
165  
166  
167  
168

169  
170  
171  
172  
173  
174  
175  
176  
177  
178  
179  
180  
181  
182  
183  
184  
185  
186  
187  
188  
189  
190  
191  
192

193 increased homogeneity and alterations in microbiota  
 194 demonstrated in water-only fasting may not be neces-  
 195 sarily due to the absence of solid food [8]. The authors  
 196 anticipated relative abundance of *Akkermansia* in  
 197 the water-only fast participants since *Akkermansia*  
 198 uses mucin as a sole substrate [48]. However, they  
 199 observed no increase in the relative abundance of  
 200 *Akkermansia* after fasting. This suggests that there  
 201 could be other bacteria that utilize mucin, which com-  
 202 pete with *Akkermansia* in the gut during water-only  
 203 fasting.

204 There are a limited number of small-scale human  
 205 studies that consider the role of *Akkermansia mucini-*  
 206 *phila*, a species of bacteria reported to thrive when  
 207 undergoing fasting conditions [43, 45], and which  
 208 may represent 3–5% of the healthy gut micro-  
 209 biota [49–50]. One small intervention study of  
 210 obese patients demonstrated significant improvement  
 211 in microbiota diversity and showed a significant  
 212 increase in *A. muciniphila* after a week of mild  
 213 fasting (Remely et al, 2015) [41]. This pilot study  
 214 [41] assigned thirteen overweight subjects to a non-  
 215 traditional fasting regimen that involved a limited  
 216 period of abstinence from solid food and natural stim-  
 217 ulants. The fasting regimen was low in energy with  
 218 an intake of 2.5 L/day of calorie-free liquid (water,  
 219 herbal tea) or vegetable broth (600–800 calories/day)  
 220 followed by a probiotic formula. Microbiota diversity  
 221 was shown to increase due to fasting and probiotic  
 222 intervention between the time points *T1* (before fast-  
 223 ing), *T2* (during fasting) and *T3* (after 6-weeks of  
 224 probiotic intervention ( $P=0.05$ ), and between the  
 225 time points *T2–T3* ( $P=0.02$ ) [41]. In addition, the  
 226 authors reported a significant increase in *Akkerman-*  
 227 *sia* between the time points (*T1–T3*:  $P=0.03$ , *T1–T2*:  
 228  $P=0.47$ , *T2–T3*:  $P=0.47$ ).

229 In a pilot study by Özkul et al., [2019] [43],  
 230 9 subjects were included in a fasting protocol  
 231 involving a 17 h fast/day for 29 days during the  
 232 month of Ramadan. A significantly increased abun-  
 233 dance of *A. muciniphila* and *B. fragilis* group was  
 234 observed in all subjects after fasting when compared  
 235 with baseline levels ( $P=0.004$  and  $0.008$ , respec-  
 236 tively). A similar Ramadan-based study involving  
 237 nine subjects by Özkul et al., [2020] [45] demon-  
 238 strated increased microbial richness ( $P=0.016$ ) and  
 239 differing microbiota composition after 29 days  
 240 vs before fasting ( $P=0.025$ ). *Butyricicoccus pulli-*  
 241 *caecorum* ( $P=0.002$ ), *Faecalibacterium prausnitzii*  
 242 ( $P=0.003$ ), and *Roseburia* ( $P=0.02$ ) were the major  
 243 species that showed a significant increase after the  
 244 end of Ramadan fasting. *A.muciniphila* ( $P=0.005$ )

245 and *Bacteroides* spp ( $P=0.02$ ) were also signifi-  
 246 cantly increased post fasting. This finding is similar  
 247 to that of Remely et al., 2015 [41] in which the  
 248 authors reported increased *A.muciniphila* in over-  
 249 weight subject post fasting. *Roseburia* has the ability  
 250 to metabolise dietary components, generate SCFAs  
 251 and influence the integrity of the intestinal epithe-  
 252 lial barrier, whilst supporting immunity with its  
 253 anti-inflammatory capabilities [51]. *F. prausnitzii*  
 254 is an anti-inflammatory commensal bacterium that  
 255 also produces SCFAs [52], whilst *B. pullicaecorum*  
 256 has recently been shown to be one of the main  
 257 butyrate-producing bacterial species with the ability  
 258 to promote intestinal epithelial barrier integrity with  
 259 its anti-inflammatory capabilities. Furthermore, in a  
 260 2018 study [53] in an antibiotic-disrupted microbiota,  
 261 depleted *B. pullicaecorum* was observed.

262 Finally, in a 12-week pilot study by Gabel et al.  
 263 2020 [44], 14 obese adults were allocated to daily 8-  
 264 hour feeding/16-hour fasting TRF intervention. At  
 265 baseline, the two most common phyla were Fir-  
 266 micutes and Bacteroidetes, at 61.2% and 26.9%,  
 267 respectively, of total abundance. The authors hypoth-  
 268 esized that the proportion of Firmicutes would  
 269 decrease and the proportion of Bacteroidetes would  
 270 increase with TRF, and that these improvements  
 271 would be associated with weight reduction. Whilst  
 272 the results indicated that TRF reduced body weight  
 273 ( $P<0.05$ ), TRF did not significantly alter the diver-  
 274 sity or overall gut microbiota composition, with no  
 275 significant changes in the abundance observed at the  
 276 end of the trial [44]. These findings are contradic-  
 277 tory to what has generally been observed with caloric  
 278 restricted diets [54–56], which have all reported ben-  
 279 efiticial changes in gut microbiota composition and/or  
 280 diversity. The authors concluded that in view of these  
 281 previous findings, it is possible that the weight reduc-  
 282 tion (2%) and caloric restriction (20%) produced in  
 283 their study was not sufficient and subsequently, did  
 284 not impact the gut microbiota composition benefi-  
 285 cially [44].

#### 286 4. Conclusion

287 Chronic calorie restriction (CR) has been reported  
 288 to elicit metabolic changes, including shaping the  
 289 gut microbial community in humans [57] and mice  
 290 [58]. Fecal microbiota of subjects exercising long-  
 291 term CR may also be more diverse and richer than in  
 292 individuals consuming Western-style diets [59–61].  
 293 Data suggests that chronic CR is, however, difficult

to adhere to [62] and thus IF could be a more feasible method for compliance. Although, it still needs to be established whether individuals can maintain IF for long terms or obtain the similar IF benefits observed in animal studies [63–65]. Furthermore, it is still not known which individuals would benefit the most from IF, which form of IF is the most effective, whether there are sex-based differences, or variations between healthy individuals and those present with certain disease. In addition, all the relevant studies have small sample sizes, a drawback that limits the generalizability of the observed effects. Therefore, future research should take these limitations into consideration for better understanding of the role of IF on gut health.

In conclusion, whilst current research is still in its infancy stage, findings of the available human studies, thus far, suggest that IF may play a potentially beneficial role in enhancing changes in gut microbiota composition and diversity. Fasting has been demonstrated to increase the abundance of protective, beneficial microbial families, such as Bifidobacteriaceae, Lactobacillaceae and Akkermansiaceae. The initial findings may be promising for the use of fasting to beneficially influence and alter the gut microbiota. However, further confirmation is warranted, with larger clinical trials with longer observation timeframes needed to replicate the available findings before clinical recommendations may be made on the role of IF in the gut health.

### Conflicts of interest

KLW conceived the review idea and wrote the first draft of the manuscript. MA contributed to the article search and revision of the manuscript. The authors have no proprietary, financial, professional or other personal interest of any nature in any product, service or company. The authors alone are responsible for the content and writing of the paper.

### Funding

This work was not supported by any grant or other form of funding.

### References

- [1] St-Onge M-P, Ard J, Baskin ML, Chiuve SE, Johnson HM, Kris-Etherton P, et al. Meal timing and frequency: implications for cardiovascular disease prevention: a scientific

- statement from the American Heart Association. *Circulation* [Internet]. 2017;135:e96-121.
- [2] Varady KA, Bhutani S, Church EC, Klempel MC. Short-term modified alternate-day fasting: a novel dietary strategy for weight loss and cardioprotection in obese adults. *Am J Clin Nutr*. 2009;90:1138-43.
- [3] Collier R. Intermittent fasting: The science of going without. *CMAJ*. 2013;185:E363-4.
- [4] Sutton E, Beyl R, Early K, Cefalu W, Ravussin E, Peterson C. Early Time-Restricted Feeding improves insulin sensitivity, blood pressure, and oxidative stress even without weight loss in men with prediabetes. *Cell Metab*. 2018;27(6):1212-1221.e3.
- [5] Anton SD, Moehl K, Donahoo WT, Marosi K, Lee SA, Mainous AG, et al. Flipping the metabolic switch: understanding and applying the health benefits of fasting. *Obesity*. 2018;26:254.
- [6] Moro T, Tinsley G, Bianco A, Marcolin G, Pacelli Q, Battaglia G, Palma A. Effects of eight weeks of time-restricted feeding (16/8) on basal metabolism, maximal strength, body composition, inflammation, and cardiovascular risk factors in resistance-trained males. *J Transl Med*. 2016;14:291.
- [7] Lederberg J, McCray AT. 'Ome Sweet 'Omics—a genealogical treasury of words. *Scientist*. 2001;15:8.
- [8] He Y, Yin J, Lei J, Liu F, Zheng H, Wang S, Wu S, Sheng H, McGovern E, Zhou H. Fasting challenges human gut microbiome resilience and reduces *Fusobacterium*. *Medicine in Microecology* 1-2. 2019;100003.
- [9] Johnson AJ, Vangay P, Al-Ghalith GA, Hillmann BM, Ward TL, Shields-Cutler RR, et al. Daily sampling reveals personalized diet-microbiome associations in humans. *Cell Host Microbe*. 2019;25(6):789-802.
- [10] Rajilić-Stojanović M, de Vos WM. The first 1000 cultured species of the human gastrointestinal microbiota. *FEMS Microbiol Rev*. 2014;38:996-1047.
- [11] Flint HJ, Duncan SH, Scott KP, Louis P. Interactions and competition within the microbial community of the human colon: links between diet and health. *Environ Microbiol*. 2007; 9:1101-11.
- [12] Walker AW, Ince J, Duncan SH, Webster LM, Holtrop G, Ze X, et al. Dominant and diet-responsive groups of bacteria within the human colonic microbiota. *ISME J*. 2011;5: 220-30.
- [13] Bäckhed F, Ley RE, Sonnenburg JL, Peterson DA, Gordon JL. Host-bacterial mutualism in the human intestine. *Science*. 2005;307:1915-20.
- [14] Topping DL, Clifton PM. Short-chain fatty acids and human colonic function: roles of resistant starch and non-starch polysaccharides. *Physiol Rev*. 2001;81:1031-64.
- [15] Natividad JM, Verdu EF. Modulation of intestinal barrier by intestinal microbiota: Pathological and therapeutic implications. *Pharmacol. Res*. 2013;69:42-51.
- [16] Gensollen T, Iyer SS, Kasper DL, Blumberg RS. How colonization by microbiota in early life shapes the immune system. *Science*. 2016;352:539-44.
- [17] Theyab A, Almutairi T, Al-Suwaidi A, Bendriss G, McVeigh C, Chaari A. Epigenetic effects of gut metabolites: Exploring the path of dietary prevention of Type 1 diabetes. *Front Nutr*. 7:563605.
- [18] Arpaia N, Campbell C, Fan X, Dikiy S, van der Veeken J, Deroos P, Liu H, Cross JR, Pfeiffer K, Coffey PJ, et al. Metabolites produced by commensal bacteria promote peripheral

339  
340  
341  
342  
343  
344  
345  
346  
347  
348  
349  
350  
351  
352  
353  
354  
355  
356  
357  
358  
359  
360  
361  
362  
363  
364  
365  
366  
367  
368  
369  
370  
371  
372  
373  
374  
375  
376  
377  
378  
379  
380  
381  
382  
383  
384  
385  
386  
387  
388  
389  
390  
391  
392  
393  
394  
395  
396  
397  
398  
399  
400

- 401 regulatory T-cell generation. *Nature*. 2013;504(7480):  
451-5. 463
- 402 [19] Furusawa Y, Obata Y, Fukuda S, Endo TA, Nakato G, Taka- 464  
403 hashi D, Nakanishi Y, Uetake C, Kato K, Kato T, et al. 465  
404 Commensal microbe-derived butyrate induces the differentia- 466  
405 tion of colonic regulatory T cells. *Nature*. 2013;504(7480): 467  
406 446-50. 468
- 407 [20] Smith PM, Howitt MR, Panikov N, Michaud M, Gallini CA, 469  
408 Bohlooly YM, Glickman JN, Garrett WS. The microbial 470  
409 metabolites, short-chain fatty acids, regulate colonic Treg cell 471  
410 homeostasis. *Science*. 2013;341:569-73. 472
- 411 [21] Alegre M, Mannon R, Mannon P. The microbiota, the 473  
412 immune system and the allograft. *Am J Transplant*. 2014; 474  
413 14(6):1236-48. 475
- 414 [22] Zimmer J, Lange B, Frick J-S, Sauer H, Zimmermann K, 476  
415 Schwiertz A, et al. A vegan or vegetarian diet substantially 477  
416 alters the human colonic faecal microbiota. *Eur J Clin Nutr*. 478  
417 2012;66:53-60. 479
- 418 [23] De Filippis F, Pellegrini N, Vannini L, Jeffery IB, La Storia 480  
419 A, Laghi L, et al. High-level adherence to a Mediterranean 481  
420 diet beneficially impacts the gut microbiota and associated 482  
421 metabolome. *Gut*. 2016;65:1812-21. 483
- 422 [24] Klinder A, Shen Q, Heppel S, Lovegrove JA, Rowland I, 484  
423 Tuohy KM. Impact of increasing fruit and vegetables and 485  
424 flavonoid intake on the human gut microbiota. *Food Funct*. 486  
425 2016;7(4):1788-96. 487
- 426 [25] Tomova A, Bukovsky I, Rembert E, Yonas W, Alwarith J, 488  
427 Barnard M, Kahleova H. The effects of vegetarian and vegan 489  
428 diets on gut microbiota. *Front Nutr*. 2019;6:47. 490
- 429 [26] Zmora N, Suez J and Elinav E. You are what you eat: diet, 491  
430 health and the gut microbiota. *Nat Rev Gastroenterol Hepatol*. 492  
431 2019;16(1):35-56. 493
- 432 [27] Ukhanova M, Wang X, Baer DJ, Novotny JA, Fredborg M, 494  
433 Mai V. Effects of almond and pistachio consumption on gut 495  
434 microbiota composition in a randomised cross-over human 496  
435 feeding study. *Br J Nutr*. 2014;111:2146-52. 497
- 436 [28] Hernández-Alonso P, Cañueto D, Giardina S, Salas-Salvadó 498  
437 J, Cañellas N, Correig X, et al. Effect of pistachio con- 499  
438 sumption on the modulation of urinary gut microbiota-related 500  
439 metabolites in prediabetic subjects. *J Nutr Biochem*. 2017;45:  
440 48-53. 501
- 441 [29] Chang C, Lin H. Dysbiosis in gastrointestinal disorders. *Best 502  
442 Pract. Res Clin Gastroenterol*. 2016;30:3-15. 503
- 443 [30] Schroeder SO, Bäckhed F. Signals from the gut micro- 504  
444 biota to distant organs in physiology and disease. *Nat Med*. 505  
445 2016;22:1079-89. 506
- 446 [31] Kho Z, Lal S. The Human Gut Microbiome - A Potential 507  
447 Controller of Wellness and Disease. *Front Microbiol*. 2018; 508  
448 9:1835. 509
- 449 [32] Frank DN, Amand ALS, Feldman RA, Boedeker EC, Harpaz 510  
450 N, Pace NR. Molecular-phylogenetic characterization of 511  
451 microbial community imbalances in human inflammatory 512  
452 bowel diseases. *Proc Natl Acad Sci USA*. 2007;104:13780-5. 513
- 453 [33] Mondot S, Kang S, Furet JP, Aguirre de Cárcer D, 514  
454 McSweeney C, Morrison M, Marteau P et al. Highlighting 515  
455 new phylogenetic specificities of Crohn's disease microbiota. 516  
456 *Inflamm Bowel Dis*. 2010;17:185-92. 517
- 457 [34] Hedin CR, McCarthy NE, Louis P, Farquharson FM, McCart- 518  
458 ney S, Taylor K, Prescott NJ, et al. Altered intestinal micro- 519  
459 biota and blood T cell phenotype are shared by patients with 520  
460 Crohn's disease and their unaffected siblings. *Gut*. 2014;63:  
461 1578-86. 521
- 462 [35] Li J, Butcher J, Mack D, Stintzi A. Functional impacts of the 522  
463 intestinal microbiome in the pathogenesis of inflammatory 523  
464 bowel disease. *Inflamm. Bowel Dis*. 2014;21:139-53. 524
- 465 [36] David LA, Maurice CF, Carmody RN, Gootenberg DB, But- 525  
466 ton JE, Wolfe BE, et al. Diet rapidly and reproducibly alters 526  
467 the human gut microbiome. *Nature*. 2014;505:559-63. 527
- 468 [37] Zeng MY, Inohara N, Nuñez G. Mechanisms of inflamma- 528  
469 tion-driven bacterial dysbiosis in the gut. *Mucosal Immunol*. 529  
470 2017;10:18-26. 530
- 471 [38] Lozupone C, Stombaugh J, Gordon J, Jansson J, Knight R. 531  
472 Diversity, stability and resilience of the human gut micro- 532  
473 biota. *Nature*. 2012;489(7415):220-30. 533
- 474 [39] Le Chatelier E, Nielsen T, Qin J, Prifti E, Hildebrand F, 534  
475 Falony G, Almeida M, Arumugam M, Batto JM, Kennedy 535  
476 S, et al. Richness of human gut microbiome correlates with 536  
477 metabolic markers. *Nature*. 2013;500:541-6. 537
- 478 [40] Heiman ML, Greenway FL. A healthy gastrointestinal 538  
479 microbiome is dependent on dietary diversity. *Molecular 539  
480 Metabolism*. 2016;5:317-20. 540
- 481 [41] Remely M, Hippe B, Geretschlaeger I, Stegmayer S, Hoefinger 541  
482 I, Haslberger A. Increased gut microbiota diversity and 542  
483 abundance of *Faecalibacterium prausnitzii* and *Akkermansia* 543  
484 after fasting: a pilot study. *Wien Klin Wochenschr*. 544  
485 2015;127(9-10):394-8. 545
- 486 [42] Cignarella F, Cantoni C, Ghezzi L, Salter A, Dorsett Y, Chen 546  
487 L, Phillips D, Weinstock GM, Fontana L, Cross AH, Zhou 547  
488 Y, Piccio L. Intermittent Fasting Confers Protection in CNS 548  
489 Autoimmunity by Altering the Gut Microbiota. *Cell Metab*. 549  
490 2018;27(6):1222-35. 550
- 491 [43] Özkul C, Yalınay M, Karakan T. Islamic fasting leads to an 551  
492 increased abundance of *Akkermansia muciniphila* and *Bacteroides* 552  
493 *fragilis* group: A preliminary study on intermittent 553  
494 fasting. *Turk J Gastroenterol*. 2019;30(12):1030-5. 554
- 495 [44] Gabel K, Marcell J, Cares K, Kalam F, Cienfuegos S, Ezpeleta 555  
496 M, Varady KA. Effect of time restricted feeding on the gut 556  
497 microbiome in adults with obesity: A pilot study. *Nutr Health*. 557  
498 2020;260106020910907. 558
- 499 [45] Özkul C, Yalınay M, Karakan T. Structural changes in gut 559  
500 microbiome after Ramadan fasting: a pilot study. *Benef 560  
501 Microbes*. 2020:1-8. 561
- 502 [46] Atarashi K, Tanoue T, Shima T, Imaoka A, Kuwahara 562  
503 T, Momose Y, Cheng G, Yamasaki S, Saito T, Ohba Y, 563  
504 et al. Induction of colonic regulatory T cells by indigenous 564  
505 *Clostridium* species. *Science*. 2011;331:337-41. 565
- 506 [47] Miyake S, Kim S, Suda W, Oshima K, Nakamura M, Mat- 566  
507 suoka T, Chihara N, Tomita A, Sato W, Kim SW, et al. 567  
508 Dysbiosis in the Gut Microbiota of Patients with Multiple 568  
509 Sclerosis, with a Striking Depletion of Species Belonging to 569  
510 *Clostridia* XIVa and IV Clusters. *PLoS one*. 2015;1:e0137429. 570
- 511 [48] Geerlings S, Kostopoulos I, de Vos W, Belzer C. *Akkerman- 571  
512 sia muciniphila* in the Human Gastrointestinal Tract: When, 572  
513 Where, and How? *Microorganisms*. 2018;6(3): 573
- 514 [49] Everard A, Belzer C, Guerts L, Ouwerkerk J, Druart J, 574  
515 Bindels L, Guiot Y, et al. Cross-talk between *Akkermansia 575  
516 muciniphila* and intestinal epithelium controls diet-induced 576  
517 obesity. *Proceedings of the National Academy of Sciences 577  
518 of the USA* 110:9066-9071. 578
- 519 [50] Santacruz A, Collago M, Garcia-Valdes L, Segura M, Martin- 579  
520 Lagos J, Anjos T, Marti-Romero M et al. Gut microbiota 580  
521 composition is associated with body weight, weight gain, and 581  
522 biochemical parameters in pregnant women. *British Journal 582  
523 of Nutrition* 104:83-92. 583

- 525 [51] Tamanai-Shacori Z, Smida L, Bousarghin L, Loreal O, 555  
 526 Meuric V, Fong S, Bonneure-Mallet M, et al. Roseburia spp: 556  
 527 a marker of health? Future Microbiology. 12:157-70. 557  
 528 [52] Sokol H, Pigneur B, Watterlot L, Lakhdari O, Bermudez- 558  
 529 Humaran I, Gratadoux J, Blugeon S, et al. *Faecalibacterium* 559  
 530 *prausnitzii* is an anti-inflammatory commensal bacterium 560  
 531 identified by gut microbiota analysis of Crohn disease 561  
 532 patients. Proceedings of the National Academy of Sciences 562  
 533 of the USA. 105:16731-6. 563  
 534 [53] Le Bastard Q, Ward T, Sidiropoulos D, Hillman B, Chun 564  
 535 C, Sadowsky M, Knights D et al. Fecal microbiota trans- 565  
 536 plantation reverses antibiotic and chemotherapy-induced gut 566  
 537 dysbiosis in mice. Scientific Reports. 8:6219. 567  
 538 [54] Kim M, Hwang S, Park E, Bae J-W. Strict vegetarian 568  
 539 diet improves the risk factors associated with metabolic 569  
 540 diseases by modulating gut microbiota and reducing intestinal 570  
 541 inflammation. Environmental Microbiology Reports. 2013;5(5):765-75. 571  
 542 [55] Heinsen F, Fangmann D, Muller N, Schulte D, Ruhlemann M, 572  
 543 Turk K, Settgast U et al. Beneficial effects of a dietary weight 573  
 544 loss intervention on human gut microbiome diversity and 574  
 545 metabolism are not sustained during weight maintenance. 575  
 546 Obesity Facts. 2016;9(6):379-91. 576  
 547 [56] Frost F, Storck L, Kacprowski T, Gartner S, Ruhlemann M, 577  
 548 Bang C, Franke A, et al. A structured weight loss program 578  
 549 increases gut microbiota phylogenetic diversity and reduces 579  
 550 levels of Collinsella in obese type 2 diabetics: A pilot study. 580  
 551 PLoS One. 2019;14(7):e0219489. 581  
 552 [57] Zhang C, Li S, Yang L, Huang P, Li W, Wang S, Zhao G, 582  
 553 Zhang M, Pang X, Yan Z, et al. Structural modulation of 583  
 554 gut microbiota in life-long calorie-restricted mice. Nature 584  
 555 communications. 2013;4:2163. 556  
 [58] Griffin NW, Ahern PP, Cheng J, Heath AC, Ilkayeva O, New- 557  
 558 gard CB, Fontana L, and Gordon JI). Prior Dietary Practices 558  
 and Connections to a Human Gut Microbial Metacommunity 559  
 Alter Responses to Diet Interventions. Cell Host Microbe. 560  
 2017;21:84-96. 561  
 [59] Davis C. The gut microbiome and its role in obesity. Nutr. 562  
 Today. 2016;51(4):167-74. 563  
 [60] Hills R, Pontefract B, Mishcon H, Black C, Sutton S, The- 564  
 565 berge C. Gut microbiome: Profound Implications for diet and 565  
 disease. Nutrients. 2019;11(7):1613. 566  
 [61] Klement R and Paziema V. Impact of different types of diet on 567  
 gut microbiota profiles and cancer prevention and treatment. 568  
 Medicine 2019;55(4):81. 569  
 [62] Carter S, Clifton P, Keogh J. Effect of Intermittent Compared 570  
 With Continuous Energy Restricted Diet on Glycemic Control in 571  
 Patients with Type 2 Diabetes A Randomized Noninferiority Trial. 572  
 JAMA Netw Open. 2018;1(3): 573  
 e180756. 574  
 [63] Antoni R, Johnston KL, Collins AL, Robertson MD. Effects 575  
 of intermittent fasting on glucose and lipid metabolism. Proc 576  
 Nutr Soc. 2017:1-8. 577  
 [64] Harvie M, Howell A. Potential Benefits and Harms of Inter- 578  
 579 mittent Energy Restriction and Intermittent Fasting Amongst 579  
 Obese, Overweight and Normal Weight Subjects-A Narrative 580  
 Review of Human and Animal Evidence. Behav Sci (Basel). 581  
 2017;7. 582  
 [65] Patterson RE, Sears DD. Metabolic Effects of Intermittent 583  
 Fasting. 2017. Annu Rev Nutr. 2017;37:371-93. 584

Uncorrected Article